C 반응성 단백질 검사 시장 : 제품, 기술별, 검사 유형별, 검체 유형별, 용도별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The C-Reactive Protein Testing Market is projected to grow by USD 3.86 billion at a CAGR of 6.85% by 2032.

C-reactive protein testing measures CRP, an acute-phase protein produced by the liver in response to inflammation. In clinical practice, standard CRP testing supports assessment of infection, inflammatory disorders, postoperative complications, and treatment response, while high-sensitivity CRP testing supports cardiovascular risk stratification when interpreted alongside established risk factors such as age, blood pressure, cholesterol, diabetes status, smoking, and family history.

Demand is supported by the global burden of noncommunicable and infectious diseases. The World Health Organization identifies cardiovascular disease as the leading cause of death worldwide, and the CDC reports heart disease as the leading cause of death in the United States. Because CRP testing is inexpensive, widely available, and compatible with central laboratory, automated analyzer, and point-of-care workflows, it remains a practical inflammatory biomarker across hospitals, diagnostic laboratories, ambulatory care, emergency departments, and chronic disease management programs.

Transformative Shifts in the CRP Testing Landscape

The CRP testing landscape is shifting from episodic inflammation testing toward integrated inflammation monitoring. Health systems are increasingly using CRP alongside complete blood count, procalcitonin, erythrocyte sedimentation rate, lipid panels, imaging, microbiology results, and clinical scoring systems to improve diagnostic confidence, support triage, and reduce unnecessary interventions.

Three forces are reshaping adoption: decentralization of diagnostics, growth of high-sensitivity CRP assays, and demand for faster clinical decisions. Point-of-care CRP testing is increasingly relevant in primary care, pediatrics, urgent care, and emergency settings where rapid triage can support antimicrobial stewardship and timely referral. At the same time, laboratory automation, immunoturbidimetric methods, and standardized quality-control processes continue to improve throughput, reproducibility, and cost efficiency for high-volume testing.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence CRP testing through decision support rather than replacing the assay itself. Machine learning models can combine CRP values with vital signs, imaging findings, medication history, comorbidities, microbiology results, and longitudinal laboratory data to identify patients at higher risk of sepsis, cardiovascular events, autoimmune flares, or postoperative complications.

The cumulative impact is strongest in workflow optimization, risk stratification, and interpretation. AI-enabled laboratory information systems and electronic health records can flag abnormal CRP trajectories, support reflex testing protocols, prioritize urgent review, and reduce manual workload. However, because CRP is a nonspecific marker of inflammation, clinically safe AI adoption depends on transparent models, validated datasets, bias monitoring, cybersecurity controls, regulatory compliance, and physician oversight.

Key Regional Insights

Asia-Pacific is advancing as China, India, Japan, South Korea, and Australia invest in hospital infrastructure, chronic disease screening, primary care access, and laboratory automation. The region combines large patient populations with rising cardiovascular, diabetes, obesity, and autoimmune disease burdens, creating sustained demand for standard CRP and high-sensitivity CRP testing across public hospitals, private laboratories, and outpatient care networks.

North America remains a mature, innovation-led region supported by high diagnostic utilization, advanced clinical laboratory infrastructure, established cardiovascular risk assessment pathways, and broad adoption of electronic health records. Latin America shows steady momentum as Brazil and Mexico expand access to private diagnostics, hospital-based testing, and infectious disease evaluation, although uneven healthcare funding and regional disparities influence adoption. Europe benefits from universal or near-universal healthcare systems, quality-assured laboratories, antimicrobial stewardship initiatives, and cardiovascular prevention programs. The Middle East is advancing through hospital modernization, medical tourism, and investment in tertiary care, particularly in GCC countries. Africa presents long-term potential as infectious disease management, maternal care, emergency medicine, and primary healthcare diagnostics improve, but affordability, laboratory capacity, workforce availability, and supply chain reliability remain key constraints.

Key Group Insights

ASEAN markets are gaining relevance as Indonesia, Vietnam, Thailand, Malaysia, Singapore, and the Philippines expand primary care capacity, hospital networks, and diagnostic laboratory access. CRP testing aligns with regional priorities in infection management, fever evaluation, noncommunicable disease monitoring, and affordable point-of-care diagnostics, particularly where rapid decision-making can reduce avoidable antibiotic use and unnecessary referrals.

The GCC is characterized by high healthcare investment, hospital modernization, chronic disease screening, and strong demand for premium diagnostic platforms, especially in Saudi Arabia and the United Arab Emirates. The European Union emphasizes standardized quality systems, in vitro diagnostic regulation, data protection, and evidence-based clinical pathways, supporting consistent laboratory adoption. BRICS countries represent scale-driven opportunity due to large populations, expanding health insurance coverage, and rising chronic disease burden. G7 markets lead in automation, high-sensitivity CRP assay adoption, digital health integration, and clinical guideline alignment, while NATO member countries generally benefit from resilient procurement systems, advanced hospital laboratory networks, and cross-border health security priorities.

Key Country Insights

The United States leads in clinical volume, high-sensitivity CRP utilization, cardiovascular risk assessment, and integrated diagnostic workflows, supported by advanced hospital systems, preventive cardiology practices, and widespread laboratory automation. Canada shows stable adoption through publicly funded healthcare, chronic disease management programs, and quality-controlled laboratory networks. Mexico and Brazil are expanding through private laboratory chains, hospital investment, and growing awareness of inflammation-based diagnostics for infection, cardiovascular disease, and metabolic disorders.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established laboratory networks, national health systems, antimicrobial stewardship programs, and guideline-driven care, while Russia maintains demand through large hospital systems and infectious disease evaluation. China and India represent major growth engines because of population scale, expanding healthcare access, rising middle-class utilization of diagnostics, and increasing cardiovascular and metabolic disease prevalence. Japan, South Korea, and Australia show strong adoption of automated, quality-controlled testing, with demand linked to aging populations, preventive healthcare, digital laboratory systems, and advanced clinical diagnostics.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize assay reliability, clinical utility, and workflow integration. Diagnostic manufacturers can strengthen competitiveness by offering high-sensitivity CRP assays with strong precision at low concentration ranges, scalable reagent supply, robust quality-control materials, and compatibility with automated chemistry analyzers, immunoassay platforms, and point-of-care systems.

Healthcare providers should embed CRP testing into evidence-based protocols rather than using it as a standalone diagnostic. Laboratories should invest in quality control, clinician education, interoperability, turnaround-time optimization, and clear interpretive guidance. Commercial teams should focus on cardiovascular risk management, infection triage, antimicrobial stewardship, autoimmune disease monitoring, postoperative surveillance, and outpatient diagnostics while maintaining transparent messaging about CRP's nonspecific nature and the need for clinical correlation.

Research Methodology

This executive summary is based on secondary research from public health agencies, clinical guideline bodies, peer-reviewed literature, regulatory references, and established diagnostic practice standards. Sources considered include the World Health Organization, CDC, national health services, cardiovascular guideline frameworks, antimicrobial stewardship guidance, laboratory medicine literature, and published evidence on CRP and high-sensitivity CRP clinical use.

The analysis applies a structured market intelligence approach: disease-burden mapping, healthcare infrastructure assessment, technology trend evaluation, regional adoption comparison, regulatory context review, and clinical workflow assessment. Insights are synthesized qualitatively to avoid unsupported numerical claims and to maintain alignment with verified, data-backed evidence without using market sizing, market share, or forecasting.

Conclusion

C-reactive protein testing remains a foundational inflammatory biomarker because it is accessible, cost-effective, rapid, and clinically useful across multiple care settings. Its relevance is expanding as health systems pursue earlier risk identification, antimicrobial stewardship, cardiovascular prevention, postoperative monitoring, and longitudinal disease management.

Future momentum will depend on high-sensitivity assay performance, point-of-care expansion, AI-assisted interpretation, digital workflow integration, and stronger alignment with clinical pathways. Organizations that pair reliable CRP testing with evidence-based decision support, quality assurance, and clinician education will be best positioned to create value in the evolving C-reactive protein testing landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. C-Reactive Protein Testing Market, by Product

• 7.1. Instruments
  • 7.1.1. Laboratory Analyzers
  • 7.1.2. Point-Of-Care Analyzers
• 7.2. Reagents & Kits
  • 7.2.1. Crp Kits
  • 7.2.2. Hs-Crp Kits
• 7.3. Software & Services
  • 7.3.1. Consulting Services
  • 7.3.2. Data Management Software

8. C-Reactive Protein Testing Market, by Technology

• 8.1. Elisa
• 8.2. Immunoturbidimetric
  • 8.2.1. Latex Enhanced
  • 8.2.2. Turbidimetric
• 8.3. Nephelometry

9. C-Reactive Protein Testing Market, by Test Type

• 9.1. Quantitative
  • 9.1.1. Automated Tests
  • 9.1.2. Manual Tests
• 9.2. Semi-Quantitative
  • 9.2.1. Immunophoresis Tests
  • 9.2.2. Lateral Flow Tests

10. C-Reactive Protein Testing Market, by Sample Type

• 10.1. Plasma
  • 10.1.1. Edta Plasma
  • 10.1.2. Heparin Plasma
• 10.2. Serum
• 10.3. Whole Blood
  • 10.3.1. Capillary Blood
  • 10.3.2. Venous Blood

11. C-Reactive Protein Testing Market, by Application

• 11.1. Cancer
• 11.2. Cardiovascular Diseases
  • 11.2.1. Coronary Heart Disease
  • 11.2.2. Stroke
• 11.3. Diabetes
• 11.4. Infection & Inflammatory Disorders
  • 11.4.1. Autoimmune Disorders
  • 11.4.2. Bacterial Infections
  • 11.4.3. Viral Infections

12. C-Reactive Protein Testing Market, by End User

• 12.1. Academic & Research Institutes
• 12.2. Clinics
  • 12.2.1. Tier I Clinics
  • 12.2.2. Tier II Clinics
• 12.3. Diagnostic Laboratories
• 12.4. Hospitals

13. C-Reactive Protein Testing Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. C-Reactive Protein Testing Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. C-Reactive Protein Testing Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories, Inc.
• 17.2. Abcam PLC
• 17.3. Alere Inc.
• 17.4. Bio-Rad Laboratories, Inc.
• 17.5. bioMerieux SA
• 17.6. BODITECH MED, INC
• 17.7. CTK Biotech Inc.
• 17.8. Danaher Corporation
• 17.9. DiaSorin S.p.A.
• 17.10. Eurolyser Diagnostica GmbH
• 17.11. F. Hoffmann-La Roche Ltd.
• 17.12. Fujifilm Corporation
• 17.13. Getein Biotech, Inc.
• 17.14. HORIBA, Ltd.
• 17.15. Lumiradx Healthcare Private Limited
• 17.16. Merck KGaA
• 17.17. Ortho Clinical Diagnostics, LLC
• 17.18. Quest Diagnostics Incorporated
• 17.19. Randox Laboratories Ltd.
• 17.20. Roche Diagnostics International AG
• 17.21. SD Biosensor, Inc.
• 17.22. Sekisui Diagnostics
• 17.23. Siemens Healthineers AG
• 17.24. Thermo Fisher Scientific, Inc.
• 17.25. Trinity Biotech PLC